Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Overall Survival (OS)

Time from randomization to death due to any cause

Time frame: Up to 34 months

Safety and tolerability of study drug (selinexor and placebo)

The safety and tolerability of study drug (selinexor and placebo) will be evaluated based on adverse event (AE) reports, physical examination results (including vital signs), and clinical laboratory results, by means of the occurrence, nature, and severity of AEs via Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0.

Time frame: From start of study drug administration up to 34 months

Time to First Subsequent Therapy (TFST)

Time from randomization until date of initiation of first therapy after discontinuation of study drug or death, whichever occurs first

Time frame: From randomization until date of initiation of first therapy after discontinuation of study drug or death, whichever occurs first (up to 34 months)

Time to Second Subsequent Therapy (TSST)

Time from randomization until date of initiation of second therapy after discontinuation of study drug or death, whichever occurs first

Time frame: From randomization until date of initiation of second therapy after discontinuation of study drug or death, whichever occurs first (up to 34 months)

Progression-free survival after initiating a next-line treatment (PFS2)

Time from randomization until the progression event after initiating a next-line treatment or death due to any cause, whichever occurs first

Time frame: From randomization until the next-line progression event or death due to any cause, up to 34 months

Progression-free Survival (PFS) as assessed by a Blinded Independent Central Review (BICR), per RECIST v1.1

Time frame: From randomization until disease progression (PD) or death, whichever occurs first (up to 34 months)

EuroQol-5 Dimensions-5 Levels Quality of Life Questionnaire (EQ-5D-5L)

EQ-5D-5L is a generic questionnaire that assesses health status as perceived by the patient across 5 categories (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and overall.

Time frame: From baseline and at specified timepoints up to 34 months